Abstract 3376: Non-small cell lung cancer (NSCLC) with higher blood tumor mutational burden (bTMB)/tissueTMB (tTMB) ratio is associated with inferior survival outcome
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3376
Abstract: Background: High TMB is known to correlate with better response to immune checkpoint inhibitor (ICI) treatment in certain cancers. bTMB is now being used in place of tTMB at times due to difficulty in obtaining… read more here.
Keywords: ttmb; btmb ttmb; ttmb ratio; btmb ... See more keywords
DNA Input, sequencing depth, and maximum somatic allele frequency may affect the concordance between blood TMB and tumor TMB.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e13163
Abstract: e13163 Background: Tumor mutation burden (TMB) is recognized as a promising biomarker for PD-1/PD-L1 blockade therapy. However, a tissue biopsy is often not available, and hence a liquid biopsy using blood can be used to… read more here.
Keywords: sequencing depth; concordance; btmb ttmb; tmb ... See more keywords
Investigating the association of blood-to-tissue tumor mutation burden (TMB) ratio with overall survival and intratumor heterogeneity (ITH) in advanced NSCLC.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.2565
Abstract: 2565 Background: High tumor mutation burden (TMB) measured via tissue-based next-generation sequencing (NGS) (tTMB) has been shown to predict better survival outcomes in certain cancers treated with immune checkpoint inhibitors (ICIs). With the increasing use… read more here.
Keywords: survival; btmb ttmb; blood; btmb ... See more keywords